Insights into the maturation heterogeneity of tumor-associated tertiary lymphoid structures in cancer immunotherapy

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19(6), 307–325 (2019). • This study underscores the growing significance of tertiary lymphoid structures (TLS) in tumor immunity due to its distinctive location and robust immune function. The integrated analysis strategy incorporating spatial and single-cell transcriptomics profoundly elucidates the immune mechanisms in tumors and their relevance to clinical immunotherapy by examining the unique structure, cellular composition and gene expression patterns within TLS. This approach is poised to substantially influence future research in the scientific field.
  Medline CASGoogle Scholar
• 2. Domblides C, Rochefort J, Riffard C et al. Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation. Front. Immunol. 12, 698604 (2021).
  Medline CASGoogle Scholar
• 3. Kinker GS, Vitiello GAF, Diniz AB et al. Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas. Gut 72(10), 1927–1941 (2023).
  Medline CASGoogle Scholar
• 4. Munoz-Erazo L, Rhodes JL, Marion VC, Kemp RA. Tertiary lymphoid structures in cancer – considerations for patient prognosis. Cell Mol. Immunol. 17(6), 570–575 (2020).
  Medline CASGoogle Scholar
• 5. Vanhersecke L, Brunet M, Guégan JP et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer 2(8), 794–802 (2021). • The findings from this study highlight the predictive capability of TLS in determining the efficacy of immune checkpoint inhibitors, independent of PD-L1 expression, presenting robust evidence for the potential development of TLS-based predictive biomarkers. Furthermore, within mature TLS, the collaboration between B cells and dendritic cells is observed to enhance the training of CD8+ T cells by facilitating the transfer of tumor antibodies, underscoring the functional intricacies within the tumor microenvironment.
  Medline CASGoogle Scholar
• 6. Posch F, Silina K, Leibl S et al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology 7(2), e1378844 (2018).
  MedlineGoogle Scholar
• 7. Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Sautès-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat. Rev. Clin. Oncol. 19(7), 441–457 (2022).
  Medline CASGoogle Scholar
• 8. Meylan M, Petitprez F, Becht E et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55(3), 527–541; e5 (2022).
  Medline CASGoogle Scholar
• 9. Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautès-Fridman C. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol. Rev. 271(1), 260–275 (2016).
  Medline CASGoogle Scholar
• 10. Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science 375(6576), eabf9419 (2022). •• The paper delves into an in-depth exploration of the current understanding of TLS in cancer, encompassing discussions on the underlying drivers of TLS formation, their pivotal function in shaping tumor immune responses, and their potential as a therapeutic target in human cancers.
  Medline CASGoogle Scholar
• 11. Siliņa K, Soltermann A, Attar FM et al. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. Cancer Res. 78(5), 1308–1320 (2018). • A key milestone of this study lies in its pioneering identification of TLS maturity using multiple fluorescent markers to predict the prognosis and treatment response in patients with solid tumors. This work underscores the significance of TLS maturity heterogeneity as an essential factor in evaluating its clinical value, potentially revolutionizing prognostic assessments in the oncological landscape.
  Medline CASGoogle Scholar
• 12. Allen E, Jabouille A, Rivera LB et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med. 9(385), 1–28 (2017).
  Google Scholar
• 13. Sato Y, Silina K, van den Broek M, Hirahara K, Yanagita M. The roles of tertiary lymphoid structures in chronic diseases. Nat. Rev. Nephrol. 19(8), 525–537 (2023).
  MedlineGoogle Scholar
• 14. Ukita M, Hamanishi J, Yoshitomi H et al. CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight 7(12), 1–15 (2022).
  Google Scholar
• 15. Dai S, Zeng H, Liu Z et al. Intratumoral CXCL13(+)CD8(+)T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. J. Immunother. Cancer 9(2), 1–10; e001823 (2021).
  Google Scholar
• 16. Truxova I, Kasikova L, Hensler M et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J. Immunother. Cancer 6(1), 139 (2018).
  MedlineGoogle Scholar
• 17. Asrir A, Tardiveau C, Coudert J et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell 40(3), 318–334; e9 (2022).
  Medline CASGoogle Scholar
• 18. Rodriguez AB, Peske JD, Woods AN et al. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 36(3), 109422 (2021).
  Medline CASGoogle Scholar
• 19. Xu W, Liu W, Yang J, Lu J, Zhang H, Ye D. Stimuli-responsive nanodelivery systems for amplifying immunogenic cell death in cancer immunotherapy. Immunol. Rev. doi: 10.1111/imr.13237 (2023) (Epub ahead of print).
  Google Scholar
• 20. Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17(12), 725–741 (2020).
  MedlineGoogle Scholar